Navigation Links
ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
Date:3/6/2009

disease.

The Company believes that microplasmin may represent a major advance in this area, as detaching the vitreous from the retina has been associated with greatly reducing the growth of new blood vessels (neovascularization) on the retina, which plays a fundamental role in the loss of vision in many diabetic patients.

Dr. Steve Pakola, Chief Medical Officer of ThromboGenics, commented, "We are very pleased to announce the completion of enrolment in MIVI II DME. This initial study is an important first step in evaluating microplasmin's effect in the diabetic retinopathy population in general. Microplasmin could represent an important treatment option for this patient population, given numerous studies from various groups showing the clinical benefits of vitreous detachment in diabetic retinopathy."

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company's lead product Microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at '/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
2. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
3. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
4. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
5. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
6. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
7. Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
8. PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
9. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
10. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
11. Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  TNI BioTech, Inc. (OTCQB: TNIB) ("TNIB" ... the development, marketing and distribution of opioid-related immunotherapies, ... materials with the Securities and Exchange Commission in ... to be held on Thursday, September 4, 2014, ... date for determining those shareholders eligible to receive ...
(Date:7/28/2014)... 2014 ResMed (NYSE: RMD ), ... cura dei disturbi respiratori del sonno (SDB) e altre ... in Germania contro il produttore Taiwanese di dispositivi medicali, ... apparecchiature da indossare in testa, che violano i brevetti, ... La sentenza della Corte Regionale Distrettuale di ...
(Date:7/28/2014)... , July 28, 2014  ResMed (NYSE: ... products for the treatment of sleep-disordered breathing and other ... Germany against Taiwanese medical device ... headgear used on APEX WiZARD 210 and 220 masks.  ... in Munich , is appealable, and ...
Breaking Medicine Technology:TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3ResMed riceve un'ingiunzione permanente contro APEX in Germania, continua a far valere i propri diritti per i brevetti in Europa 2ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2
... Dec. 30, 2011 /PRNewswire-Asia-FirstCall/ -- Concord Medical Services ... CCM ), operator of the largest ... China, comments on the newly issued Foreign Investment ... healthcare service sectors to "permitted" from "restricted" category. ...
... BioDelivery Sciences International, Inc. (Nasdaq: BDSI ) ... Food and Drug Administration (FDA) that a Risk Evaluation ... been approved.  The program, which will be referred to ... Program, was designed to ensure informed risk-benefit decisions before ...
Cached Medicine Technology:Healthcare Services No Longer "Restricted" in China's Foreign Investment Catalogue 2Healthcare Services No Longer "Restricted" in China's Foreign Investment Catalogue 3ONSOLIS to Benefit from Approval of Class-Wide REMS for All Transmucosal Fentanyl Products 2ONSOLIS to Benefit from Approval of Class-Wide REMS for All Transmucosal Fentanyl Products 3ONSOLIS to Benefit from Approval of Class-Wide REMS for All Transmucosal Fentanyl Products 4
(Date:7/28/2014)... Philadelphia, PA (PRWEB) July 28, 2014 ... die each year from metastatic breast and prostate cancers ... when the cancer has spread to other parts of ... brain. Now researchers at Drexel University College of ... target they identified that inhibits metastatic progression by blocking ...
(Date:7/28/2014)... Randy Dotinga HealthDay Reporter ... it takes humans just milliseconds to look at someone,s face ... new study finds that certain facial features seem to trigger ... shape and size of the mouth, for example, appear directly ... keys to attractiveness. The study findings suggest that ...
(Date:7/28/2014)... of a surgical procedure to treat severe chronic migraine ... percent of the time in patients treated at Massachusetts ... of Plastic and Reconstructive Surgery report that more than ... all of whom had headaches associated with compression ... year later. The team,s paper has received advance ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Thousands of ... on behalf of individuals who were allegedly injured by ... continue to move forward in U.S. District Court, Northern ... an Order issued on July 18, 2014, U.S. District ... filed by the Plaintiffs’ Steering Committee that sought the ...
(Date:7/28/2014)... 2014 Glutamine is the most abundant ... to be conditionally essential during times when the body ... recovery & Immune System Support. , Having a heavy ... produces, supplementing with additional glutamine may be advantageous. Glutamine ... the body, digestion and immune system function. Stress on ...
Breaking Medicine News(10 mins):Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 2Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 3Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3
... SAN DIEGO, Sept. 14 Amylin Pharmaceuticals,Inc. (Nasdaq: ... at,an investor reception during the 43rd Annual Meeting of ... Wednesday, September 19,2007 at 4:30 a.m. PT / 1:30 ... live presentation will be webcast, and recordings will be ...
... BIRMINGHAM, Ala., Sept. 14 /PRNewswire-USNewswire/,-- ProAssurance Group ... a specialized,professional liability program designed for Michigan,s ... through Physicians Insurance Company,of Wisconsin, Inc. (PIC ... pleased to have the opportunity to serve ...
... product dissolves naturally , THURSDAY, Sept. 13 (HealthDay News) -- ... someone else,s used-up chewing gum. , But relief may be ... non -stick, easy-to-remove version of chewing gum at the BA ... be easily removed from shoes, clothes, hair and sidewalks, and ...
... Sept. 14 Michael Bond has,been named the ... following nearly 30 years in various roles for ... Blade Process,Engineering. Bond has a wealth of experience ... leading edge technologies for,IncisionTech and Specialty Blades. ...
... Stryker,Corporation (NYSE: SYK ) announced today that ... 25, 2007 - 4:30 p.m. Eastern Time UBS ... A simultaneous webcast of the Company,s presentation will ... the For Investors page. The,presentation for the UBS conference ...
... Most people looking for tax advice,usually go to an ... Here,s more on a new report that shows a ... actually not seeing the pros,trained in their field. ... Registered journalists can access video, audio, text, graphics ...
Cached Medicine News:Health News:ProAssurance Group Offers Coverage for Community Based Hospitals in Michigan 2Health News:Specialty Blades, Inc. Expands Management Team With New VP Engineering 2Health News:Stryker to Present at Investor Conference 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: